MacLean PS, Blundell JE, Mennella JA, et al. Biological control of appetite: a daunting complexity. Obesity (Silver Spring). 2017;25(Suppl 1):S8-S16.
Li Z, Heber D. Managing weight loss expectations: the challenge and the opportunity. J Am Med Assoc. 2014;311:1348-1349.
Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121(6):21-33.
Carneiro G, Zanella MT. Obesity metabolic and hormonal disorders associated with obstructive sleep apnea and their impact on the risk of cardiovascular events. Metabolism. 2018;84:76-84.
Prenner SB, Mather PJ. Obesity and heart failure with preserved ejection fraction: A growing problem. Trends Cardiovasc Med. 2018;28:322-327.
Himbert C, Delphan M, Scherer D, et al. Signals from the adipose microenvironment and the obesity-cancer link-a systematic review. Cancer Prev Res (Phila). 2017;10: 494-506.
Gorodner V, Viscido G2, Signorini F, et al. Gastroesophageal reflux disease and morbid obesity: evaluation and treatment. Updates Surg. 2018 ;70(3):331-337.
Barnes RD, Ivezaj V. A systematic review of motivational interviewing for weight loss among adults in primary care. Obes Rev. 2015;16(4):304-318.
Look AHEAD Research Group. Association of the magnitude of weight loss and physical fitness change on long-term CVD outcomes: the Look AHEAD Study. Lancet Diabetes Endocrinol. 2016;4(11):913-921.
Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096.
Salvestrini V, Sell C, Lorenzini A. Obesity may accelerate the aging process. Front Endocrinol (Lausanne).2019;10:266.
EASO Patient Council. Five key propositions for GPs. https://easo.org/education/guidelines/. Accessed May 3, 2019.
Katzmarzyk PT, Chaput J-P, Fogelholm M, et al. International Study of Childhood Obesity, Lifestyle and the Environment (ISCOLE): contributions to understanding the global obesity epidemic. Nutrients. 2019;11(4):848.
Xenical Package Insert. FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020766s026lbl.pdf. Accessed 7/19/19.
Saxenda Package insert. novo-pi.com. Available at: https://www.novo-pi.com/saxenda.pdf. Accessed 7/19/19.
Contrave Package Insert. contrave.com. Available at: https://contrave.com/content/pdf/Contrave_PI.pdf. Accessed 7/19/19.
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172.
Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.
Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Hermann Toplak, MD

Professor
Medical University Graz
Graz, Austria

Disclosures

Disclosure: Hermann Toplak, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Cheplapharm; Merck Sharp & Dohme; Mylan Laboratories Inc.; Novo Nordisk
Received grants for clinical research from: Amgen Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Faculty

Rachel Pryke, MBBS, MRCGP, FRCP

GP and Trainer
Chair GPING (GPs with an Interest in Nutrition Group)
GP representative Obesity Health Alliance
Winyates Health Centre
Worcestershire, United Kingdom

Disclosures

Disclosure: Rachel Pryke, MBBS, MRCGP, FRCP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Novo Nordisk

Editor

Robert McCarthy, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

Associate CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CPD

Are We Ready to Tackle Chronic Obesity in Primary Care?

Authors: Hermann Toplak, MD; Rachel Pryke, MBBS, MRCGP, FRCP
CPD Released: 9/4/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/4/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians (PCPs), diabetologists & endocrinologists, and cardiologists.

The goal of this activity is to enhance the knowledge of the target audience concerning the role of obesity in the development and exacerbation of a range of cardiometabolic and other disorders; the difficulty of weight loss; the problem of weight regain after weight loss; and the interventional strategies and pharmacotherapies that have shown benefit in weight loss and weight regain prevention.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Need to tackle the chronic obesity epidemic in primary care
- Enduring weight loss achievable via a collaborative and integrated approach
Have greater competence related to
- Initiating timely and coordinated weight loss intervention and engaging with the patient affected by obesity

Disclosures

Moderator

Hermann Toplak, MD

Professor
Medical University Graz
Graz, Austria

Disclosures

Disclosure: Hermann Toplak, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Cheplapharm; Merck Sharp & Dohme; Mylan Laboratories Inc.; Novo Nordisk
Received grants for clinical research from: Amgen Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Faculty

Rachel Pryke, MBBS, MRCGP, FRCP

GP and Trainer
Chair GPING (GPs with an Interest in Nutrition Group)
GP representative Obesity Health Alliance
Winyates Health Centre
Worcestershire, United Kingdom

Disclosures

Disclosure: Rachel Pryke, MBBS, MRCGP, FRCP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Novo Nordisk

Editor

Robert McCarthy, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

Associate CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and World Obesity Federation (WOF), World Organization of Family Doctors (WONCA).

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

SCOPE Certification via Medscape and SCOPE E-Learning

To obtain credit towards SCOPE Certification please email [email protected]. For more information visit www.worldobesity.org/training-and-events/training/scope/certification

To qualify for SCOPE Certification, you will need to accrue a total of 12 SCOPE points, including 4 earned by completing the SCOPE Core Learning Path. You will also need to show evidence of having at least six months’ clinical experience managing patients with overweight or obesity.
The following steps outline one route by which a healthcare professional can apply for SCOPE Certification by combining Medscape CME activities with SCOPE E-Learning modules.
All SCOPE E-Learning modules referred to below can be accessed via www.scope-elearning.org. The Core Learning Path can be accessed for £70 (with discounts available for World Obesity members and HCPs in low-and-middle income countries) and all other modules are available for free.

Step 1: Complete the SCOPE Core Learning Path
= 4 SCOPE points

Step 2: Complete the following SCOPE Accredited Medscape activities below are the programs in this year’s initiative:

1. Embracing Obesity in Collaboration – Why, When & How to Intervene? (0.5 SCOPE points)
2. Are We Ready to Tackle Chronic Obesity in Primary Care? (0.5 SCOPE points)
3. In Dialogue with the Patient with Persistent Obesity – Proven Steps to Sustained Weight Loss (0.5 SCOPE points)
4. Enduring Obesity – Long-term Strategies for a Chronic Disease (0.5 SCOPE points)
= 2.0 SCOPE points

Step 3: Complete 12 free supplementary SCOPE E-Learning modules (0.5 SCOPE points each)
= 6.0 SCOPE

You will now have the 12 SCOPE points required for SCOPE Certification.

Step 4: Email [email protected] with evidence of your clinical experience. Your application will be reviewed. Subject to approval, your SCOPE Certification will be awarded within seven working days.

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Are We Ready to Tackle Chronic Obesity in Primary Care?

Authors: Hermann Toplak, MD; Rachel Pryke, MBBS, MRCGP, FRCPFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 9/4/2019

Valid for credit through: 9/4/2020, 11:59 PM EST

processing....

Page 1 of 4

CPD Information Download Slides

Additional Resources

Expert Commentary

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Hermann Toplak, MD

Faculty

Rachel Pryke, MBBS, MRCGP, FRCP

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

CPD

Are We Ready to Tackle Chronic Obesity in Primary Care?

Target Audience and Goal Statement

Disclosures

Moderator

Hermann Toplak, MD

Faculty

Rachel Pryke, MBBS, MRCGP, FRCP

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Are We Ready to Tackle Chronic Obesity in Primary Care?

Expert Commentary